The numbers alone tell a story. When Jimini Health announced a $17 million seed round on March 31, 2026, it wasn't just another funding headline in a crowded behavioral health market. It was a bet—led by M13—that dwarfs what most healthcare startups pull together at this stage.
For context, seed rounds in healthcare typically hover between $3 and $5 million. Rock Health pegged the median digital health deal across all funding stages at $12 million in 2025. Jimini's raise clocks in at roughly three to five times typical seed-stage funding, a signal that investors see something beyond incremental improvement.
What they're backing is Sage: an AI assistant designed to sit between therapy sessions, supervised by clinicians, handling the mental health equivalent of what happens when patients leave the office. The New York-based startup isn't trying to replace therapists. It's trying to extend them.
The Product—and the Pitch
Here's how it works. A clinician defines the care plan. Sage follows it, checking in with patients, flagging risk signals when someone's language or behavior shifts, and feeding insights back to the therapist before the next session. The company describes it as keeping clinicians "in the driver's seat," which is both accurate and strategic—healthcare AI lives or dies on whether doctors trust it.
Jimini runs its own clinic to stress-test updates before rolling features out to partner providers. It's a model borrowed from the cautious side of regulated industries, where you don't ship fast and break things. You ship carefully and measure outcomes.
The approach reflects a broader shift. Behavioral health startups that went direct-to-consumer or leaned too hard into automation have stumbled; some have shuttered altogether. Jimini appears to be positioning for a different endgame: infrastructure that integrates with existing electronic health records and, eventually, payer reimbursement pathways. That's harder to build. It also might last longer.
The Team Behind the Bet
Co-founder and CEO Luis F. Voloch brings a track record from Immunai, an AI-driven immunotherapy venture, and earlier work at Palantir. President Mark Jacobstein held senior roles at Immunai and Guardant Health. Chief Product Officer Sahil Sud came from Ribbon Health's founding team—also a Palantir alum.
Recent hires deepen the clinical bench. Bill Hudenko, PhD, joined as Chief Clinical Officer from Dartmouth. Lynn Hamilton, formerly of Talkspace, took the chief commercial role. The advisory roster pulls from Harvard, Yale, Stanford, and Dartmouth, with Robert Langer among the names attached.
It's the kind of team composition that makes investors comfortable writing larger checks. Domain expertise, regulatory fluency, experience navigating both startups and established healthcare players.
Where the Money Goes
Jimini plans to scale Sage into additional care settings and cement partnerships with major U.S. behavioral health providers. Some of the capital will fund what the company calls its "regulatory-minded approach"—a polite way of saying they're preparing for the compliance gauntlet that healthcare AI inevitably faces.
The funding history offers a breadcrumb trail. Jimini raised an $8 million pre-seed in November 2024, backed by Zetta Venture Partners, LionBird, PsyMed, BoxGroup, Arkitekt Ventures, and SCB 10X. The latest round, with participation from Town Hall Ventures, LionBird, Zetta, and OneMind, pushes total capital raised past $25 million. That's substantial runway for a company founded in 2023.
The Market—and the Gamble
Behavioral health demand continues to outpace supply in the U.S., a stubborn mismatch that's created openings for technology. But the market has also chewed up and spit out companies that moved too fast or misread how clinicians and payers actually adopt new tools. AI regulation is tightening. Reimbursement remains Byzantine.
Jimini's wager is that supervised, infrastructure-level AI can navigate those constraints without sacrificing speed. The question every well-funded healthtech startup eventually faces is whether the model works at scale—and whether the economics make sense once you're no longer burning venture capital.
The $17 million seed gives Jimini time to answer that. Whether it's enough time depends on how quickly large health systems and insurers decide they trust an algorithm to sit between their patients and their therapists. The company seems to understand that trust isn't assumed. It's built one escalated risk flag, one clinician dashboard, onecare plan at a time.
